According to new research from the Monell Center and collaborating institutions, odors from human skin cells can be used to identify melanoma, the deadliest form of skin cancer.
In addition to detecting a unique odor signature associated with melanoma cells, the researchers also demonstrated that a nanotechnology-based sensor could reliably differentiate melanoma cells from normal skin cells. The findings suggest that non-invasive odor analysis may be a valuable technique in the detection and early diagnosis of human melanoma.
Melanoma is a tumor affecting melanocytes, skin cells that produce the dark pigment that gives skin its color. The disease is responsible for approximately 75 percent of skin cancer deaths, with chances of survival directly related to how early the cancer is detected. Current detection methods most commonly rely on visual inspection of the skin, which is highly dependent on individual self-examination and clinical skill.
The current study took advantage of the fact that human skin produces numerous airborne chemical molecules known as volatile organic compounds, or VOCs, many of which are odorous. “There is a potential wealth of information waiting to be extracted from examination of VOCs associated with various diseases, including cancers, genetic disorders, and viral or bacterial infections,” notes George Preti, PhD, an organic chemist at Monell who is one of the paper’s senior authors.
In the study, published online ahead of print in the Journal of Chromatography B, researchers used sophisticated sampling and analytical techniques to identify VOCs from melanoma cells at three stages of the disease as well as from normal melanocytes. All the cells were grown in culture.
The researchers used an absorbent device to collect chemical compounds from air in closed containers containing the various types of cells. Then, gas chromatography-mass spectrometry techniques were used to analyze the compounds and identified different profiles of VOCs emitting from melanoma cells relative to normal cells.
Both the types and concentrations of chemicals were affected. Melanoma cells produced certain compounds not detected in VOCs from normal melanocytes and also more or less of other chemicals. Further, the different types of melanoma cells could be distinguished from one another.
Noting that translation of these results into the clinical diagnostic realm would require a reliable and portable sensor device, the researchers went on to examine VOCs from normal melanocytes and melanoma cells using a previously described nano-sensor.
Constructed of nano-sized carbon tubes coated with strands of DNA, the tiny sensors can be bioengineered to recognize a wide variety of targets, including specific odor molecules. The nano-sensor was able to distinguish differences in VOCs from normal and several different types of melanoma cells.
“We are excited to see that the DNA-carbon nanotube vapor sensor concept has potential for use as a diagnostic. Our plan is to move forward with research into skin cancer and other diseases,” said A.T. Charlie Johnson, PhD, Professor of Physics at the University of Pennsylvania, who led the development of the olfactory sensor.
Together, the findings provide proof-of-concept regarding the potential of the two analytical techniques to identify and detect biomarkers that distinguish normal melanocytes from different melanoma cell types.
“This study demonstrates the usefulness of examining VOCs from diseases for rapid and noninvasive diagnostic purposes,” said Preti. “The methodology should also allow us to differentiate stages of the disease process.”
Current studies are focusing on analysis of VOCs from tumor sites of patients diagnosed with primary melanoma.
The Latest Bing News on:
- Breakthroughs in Melanoma From ESMO Virtual Congress 2020on October 12, 2020 at 8:00 am
Highlights in melanoma from ESMO 2020 include first-line treatment sequencing, prediction of long-term survival, and a novel combination therapy after progression, as discussed by Dr Caroline Robert.
- Melanoma Research Alliance Announces 13 Dermatology Fellowship Awardson October 9, 2020 at 3:43 am
The Melanoma Research Alliance, the largest non-profit funder of melanoma research, has named 13 promising clinicians/researchers-in-training as 2020 MRA Dermatology Fellows.
- Five-Year OS Nears 40% in BRAF Wild Type Melanomaon October 8, 2020 at 2:35 pm
Almost 40% of patients with advanced BRAF wild type melanoma remained alive at 5 years after treatment with the PD-1 inhibitor nivolumab (Opdivo), follow-up data from a randomized trial showed. By ...
- Castle Biosciences announces expanded medicare for DecisionDx-Melanoma in Cutaneous Melanomaon October 8, 2020 at 10:05 am
(NASDAQ:CSTL) announces that Palmetto GBA MolDx, a Medicare Administrative Contractor, has issued a final expanded local coverage determination or LCD for DecisionDx®-Melanoma test.The LCD effective ...
- DNA Analysis Might Reveal Melanoma Riskon October 8, 2020 at 9:42 am
DNA mutations in skin cells may signal a risk for melanoma long before it's visible to the eye, a new study suggests. Exposure to sun damages skin and DNA, and this damage can be measured. Using a new ...
- Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanomaon October 8, 2020 at 4:48 am
Castle announced that Palmetto GBA MolDx has issued a final expanded local coverage determination for the company's DecisionDx®-Melanoma test.
- Iovance Stock Down on Delay in Filing for Melanoma Candidateon October 7, 2020 at 8:32 am
Shares of Iovance Biotherapeutics, Inc. IOVA fell about 12.4% after it announced that it will delay its biologics license application (BLA) submission to the FDA for its tumor-infiltrating lymphocyte ...
- Risk of melanoma may be gauged long before suspicious moles appear – studyon October 7, 2020 at 6:02 am
Research suggests genomic methods used to probe skin damage could be developed to estimate baseline risk of the skin cancer.
- Iovance stock drops nearly 10% following snag with FDA over experimental melanoma treatmenton October 6, 2020 at 12:05 pm
Shares of Iovance Biotherapeutics, which is building a commercial manufacturing and office complex at the Philadelphia Navy Yard, were down 10% Tuesday on news about its experimental melanoma ...
- Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanomaon October 5, 2020 at 1:01 pm
(GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today provided a regulatory update for its ...
The Latest Google Headlines on:
The Latest Bing News on:
- Chemistry & Physicson October 8, 2020 at 6:56 pm
Let's Talk Science. Let's Talk Medicine. The leading scientific social networking website and producer of educational virtual events and webinars.
- Risky Breast Lumps; Bone Testing Lags in Prostate Cancer; Cancer Breathalyzer?on October 8, 2020 at 9:31 am
as adjuvant therapy for resected melanoma, and adding nivolumab to neoadjuvant chemotherapy significantly improved pathologic complete response in resectable non-small cell lung cancer ...
- CEL-SCI Corporation Issues Letter to Shareholderson September 15, 2020 at 6:18 am
If proven to work for head and neck cancer, a truly horrible disease, we believe that our unique Multikine immunotherapy will prove to be useful for a number of other solid tumors including breast ...
- Graveyard Shift Workers Don't Have Increased Cancer Riskon September 1, 2020 at 5:00 pm
“For example, studies of female flight attendants have found an increased risk of breast cancer and also a higher-than-expected risk for developing malignant melanoma ... guidelines in order to submit ...
- Could Increasing the Melanin In Your Skin Protect You From Cancer?on January 15, 2019 at 4:28 pm
Melanin serves a few very important purposes besides giving your skin its color. When you’re outside, your skin is being exposed to the ultraviolet rays of the sun. UV radiation is just that ...